MCMingfeng Cao

Mingfeng Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mingfeng Cao has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Qian Wang

    Department of Central Laboratory, Postdoctoral Workstation, The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China

    3 shared publications
  • Yuzhen Xu

    Department of Rehabilitation, The Second Affiliated Hospital of Shandong First Medical University, Taian, China

    3 shared publications
  • Jing Ji

    Department of Emergency, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China

    2 shared publications
  • Mengmeng Cui

    Department of Rehabilitation, The Second Affiliated Hospital of Shandong First Medical University, Taian 271000, China

    2 shared publications
  • Pengyu Tao

    Department of Nephrology Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China

    2 shared publications
  • Xinhuan Zhang

    Department of Endocrinology, Second Affiliated Hospital of Shandong First Medical University, Tai’an, China

    2 shared publications

Latest Publications

  • Open Access

    Study of independent diagnostic efficacy and co-diagnostic strategies of molecular markers for diabetic cardiomyopathy

    by Na Su, Jingxuan Zhao, Weiyi Zhang, Xinhuan Zhang, Kunna Lu, Yan Ma, Yan Wang, Mingfeng Cao

    Word count of the full article: 4834Diabetic cardiomyopathy (DCM) is defined as myocardial dysfunction in diabetes mellitus (DM) patients independent of coronary artery disease (CAD) or hypertension (HTN). With high morbidity and mortality, DCM poses a significant threat to patient health. Its underlying pathogenesis remains incompletely elucidated, and the prolonged subclinical phase renders early diagnosis and precise treatment clinically challenging. Thus, identifying viable biomarkers for early diagnosis and intervention has emerged as a research imperative, whereas a systematic DCM diagnostic and therapeutic strategy remains to be established. Our examination revealed that circulating soluble suppression of tumorigenicity 2 (sST2), Cardiotrophin-1 (CT-1), and galectin-3 levels correlate closely with DCM progression stages. Combining Lysyl Oxidase-Like 2 (LOXL2) and Electron Transfer Flavoprotein β Subunit (ETFβ) measurements with ultrasound E/E’ ratio and NT-proBNP enhances diagnostic accuracy. Novel noninvasive markers (e.g., skin autofluorescence) show promise. This article comprehensively evaluates the clinical applications of these molecular markers within DCM’s pathophysiological classification framework.

  • Open Access

    A systematic review and meta-analysis of microRNAs in the diagnosis of early diabetic kidney disease

    by Lujie Jiang, Li Li, Ke Zhang, Liping Zheng, Xinhuan Zhang, Yanlian Hou, Mingfeng Cao, Yan Wang

    Objective: The aim of this study was to comprehensively assess the overall diagnostic value of circulating microRNAs (miRNAs or miRs) as biomarkers for the early diagnosis of diabetic kidney disease (DKD) through Meta-analysis, and to identify potential molecular biomarkers with higher diagnostic value for early DKD.Methods: The CNKI, Wanfang date, VIP, Pubmed, Embase, Web of Science, and Cochrane Library until January 2024 were searched. Relevant studies associated with the value of miRNAs in the diagnosis of early DKD were selected. Case numbers, sensitivity, and specificity were extracted from the included literature for both the observation and control groups.Results: Nine studies including 655 cases of early DKD patients and 664 cases as a control group were conducted. The comprehensive sensitivity was 0.76, comprehensive specificity was 0.74, combined positive likelihood ratio was 2.9 and the combined negative likelihood ratio was 0.33, diagnostic odds ratio (DOR) was 9. The summary receiver operating characteristic (SROC) curve was drawn and the area under the curve (AUC) was 0.79. Blood and urine source data were analyzed and showed that urine source miRNA had a higher sensitivity (0.82vs 0.68) and a higher DOR (10.5vs 8.2) than blood source miRNA.Conclusion: MiRNAs may serve as promising noninvasive biomarkers for the early diagnosis of DKD. The diagnostic value of miRNAs in urine samples may be higher than that in blood samples. The combined detection of some miRNAs or other clinical indicators can enhance the accuracy of early DKD diagnosis.Systematic Review Registration: https://osf.io, identifier DOI: 10.17605/OSF.IO/FC6DK.


  • Open Access

    Emodin attenuate diabetic kidney disease by inhibiting ferroptosis via up regulating Nrf2 expression

    by Jing Ji, Pengyu Tao, Qian Wang, Mengmeng Cui, Mingfeng Cao, Yuzhen Xu

    Diabetic kidney disease (DKD) poses a threat to people’s health. The current treatments only provide partial relief of symptoms. Therefore, seeking a promising therapeutic medication for the prevention and control on DKD will benefit patients. Recently, a novel iron-dependent and non-apoptotic regulated mode of cell death, termed as ferroptosis, is expected to offer us a novel insight into the mechanism of DKD. We conducted experiments to investigate the role of ferroptosis in the development of DKD. Iron accumulation, weakened antioxidant capacity and ROS overproduction were observed in the renal tissues of STZ-induced diabetic rats. A persistent high glucose condition contributed to down regulated levels of Glutathione Peroxidase 4 (GPX4) and Solute Carrier Family 7 Member 11 (SLC7A11) which marked the occurrence of ferroptosis. Treatment of Emodin in DKD models could significantly attenuated these changes and reduced renal injury. Besides, NFE2-related factor 2 (Nrf2), an important antioxidant regulator, was inhibited in both in vivo and in vitro assay, which contributes to Reactive Oxygen Species (ROS) generation that further promoted the expression of ferroptosis related protein. These unwanted effects were offset by the intervention of Emodin. The specific Nrf2 knock out enhanced cell’s sensitivity to ferroptosis by being exposed to high glucose culture, which was improved by treatment of Emodin via restoring activity of Nrf2. In conclusion, our research demonstrated that Emodin exerted renal protection against DKD via inhibiting ferroptosis and restoring Nrf2 mediated antioxidant capacity, which could be employed as a novel therapeutic medication against DKD.


  • Open Access

    A commentary on ‘Preoperative carbohydrate loading with individualized supplemental insulin in diabetic patients undergoing gastrointestinal surgery: a randomized trial’

    by Hanwen Mm Cao, Ke Mm Zhang, Mingfeng Mm Cao, Xinhuan Zhang

    An abstract is unavailable. This article is available as a PDF only.


  • Open Access

    The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease

    by Pengyu Tao, Jing Ji, Qian Wang, Mengmeng Cui, Mingfeng Cao, Yuzhen Xu

    Diabetic kidney disease (DKD), an emerging global health issue, is one of the most severe microvascular complications derived from diabetes and a primary pathology contributing to end-stage renal disease. The currently available treatment provides only symptomatic relief and has failed to delay the progression of DKD into chronic kidney disease. Recently, multiple studies have proposed a strong link between intestinal dysbiosis and the occurrence of DKD. The gut microbiota-derived short-chain fatty acids (SCFAs) capable of regulating inflammation, oxidative stress, fibrosis, and energy metabolism have been considered versatile players in the prevention and treatment of DKD. However, the underlying molecular mechanism of the intervention of the gut microbiota–kidney axis in the development of DKD still remains to be explored. This review provides insight into the contributory role of gut microbiota-derived SCFAs in DKD.


  • Open Access

    Quercetin targets VCAM1 to prevent diabetic cerebrovascular endothelial cell injury

    by Jiebin Huang, Weiwei Lin, Yuxing Sun, Qian Wang, Shidian He, Zhihua Han, Lixing Lu, Xueran Kang, Yisheng Chen, Haoran Guo, et al.

    Introduction: Endothelial cells play important roles in neurodegenerative diseases caused by diabetes, therefore, we aimed at investigating the mechanisms through which endothelial cells are involved in diabetes development.Methods: Single cell analysis was performed to identify the major endothelial cell subtypes in cardiovascular tissues that are involved in diabetes development. A cell-cell communication approach was then used to identify ligand-receptor interaction pairs between these cell types. Differential expression analysis between the two experimental groups [standard chow diet group and diabetogenic diet with cholesterol (DDC) group] was used to identify diabetes-related differentially expressed genes (DEGs). The upregulated genes were used to identify candidate ligands or receptors, as well as the corresponding cell types. Cell trajectory inference was performed to identify the stage of cell development and changes in expression of candidate ligands or receptors during cell development. Gene set enrichment analysis (GSEA) was conducted to investigate the biological functions of genes of purpose. Finally, molecular dynamics simulations (MDSs) were used to predict potential drugs with the ability to target the proteins of purpose.Results: Seven cell types, including five endothelial cell subtypes (EC_1, EC_2, EC_3, EC_4, and EC_EndMT), were identified from endothelial cell-enriched single cell samples from the heart and aorta of mice. Cell-cell communication analysis revealed the potential ligand-receptor interactions between these cell types while five important ligand-receptor-associated genes, including Fn1, Vcam1, Fbn1, Col4a1, and Col4a2, were established by differential expression analysis. Among them, Vcam1 is mainly expressed in EC_EndMT and is involved in interactions between EC_EndMT and other cells. Cell trajectory extrapolation analysis revealed a shift from EC_2/EC_4 to EC_EndMT and a shift from EC_EndMT to EC_3/EC_1 during the progression of diabetes. GSEA analysis revealed that upregulation of VCAM1 may have inhibitory effects on cell growth and energy metabolism.Conclusion: EC_EndMT subtypes have a complex role in neurodegenerative diseases caused by diabetes. Through mechanisms involved in cell-cell communication, Vcam1 may play an important role in dysregulation of biological functions of EC_ EndMT. Molecular docking results of the quercetin-VCAM1 complex suggest that quercetin may be an effective drug for targeting this protein.


  • Open Access

    A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma

    by Yan Liu, Houfa Geng, Xuekui Liu, Mingfeng Cao, Xinhuan Zhang

    Background: Aim of this meta-analysis was to evaluate the overall diagnostic value of circulating mini miRNAs for papillary thyroid carcinoma (PTC) and to find the possible molecular marker with higher diagnostic value for PTC. Methods: We searched the Pubmed, Cochrane and Embase database until June 2020. We selected relevant literatures associated with the diagnosis of PTC with circulating miRNAs. The number of cases in experimental group and the control group, sensitivity and specificity could be extracted from the literatures. Results: We got 9 literatures including 2114 cases of PTC. Comprehensive sensitivity was 0.79, comprehensive specificity was 0.82, positive likelihood ratio was 4.3, negative likelihood ratio was 0.26, diagnostic advantage ratio was 16. The summary receiver operating characteristic curve was drawn and the Area Under the Curve was 0.87. Conclusions: Circulating microRNAs may be promising molecular markers for the diagnosis of papillary thyroid carcinoma. Combined detection of certain serum microRNAs can improve the diagnostic accuracy of papillary thyroid carcinoma. Especially MiR-222 and miR-146b may be prime candidates for the diagnosis of PTC in Asian population.